A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
about
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerDNA-repair pathway inhibitors for the treatment of ovarian cancerSurvival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersOvarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionCellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsThe role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapyTargeting DNA damage response in cancer therapyPARP inhibitors and moreTherapeutic targeting of cancers with loss of PTEN function.Understanding specific functions of PARP-2: new lessons for cancer therapyPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineIs it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentPrecision targeted therapy of ovarian cancerNew perspectives on targeted therapy in ovarian cancerNuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancerIdentification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1Diverse small molecule inhibitors of human apurinic/apyrimidinic endonuclease APE1 identified from a screen of a large public collectionCan oncology recapitulate paleontology? Lessons from species extinctionsReduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibitionA phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group studyBRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursMethotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.Major clinical research advances in gynecologic cancer 2009.Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Bioenergetic metabolites regulate base excision repair-dependent cell death in response to DNA damage.Targeted therapies in epithelial ovarian cancer."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsTargeted therapy in ovarian cancer.Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions.Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.
P2860
Q24187899-A142457A-1D94-4502-8F6D-815099CACB2BQ24234893-909F781D-5F11-47E9-A735-6876AF3EB41CQ24654487-DF2587FA-C6DD-4866-BE8F-7E30657C867AQ26744525-341A0EA9-FD6A-4A18-BD37-9F778D71F81DQ26771165-DA10254B-4E13-4ED5-90A9-A18165F78638Q26851765-FC39F808-B822-4E5E-8049-6B0E70927740Q26852274-B98EC6D6-6D28-4BBB-BC5C-81E542B59807Q27010084-147559F0-C4C3-49F5-BB0B-76AB377B048BQ27023204-30A45FAD-7E58-4865-83EE-EC2357185387Q27027014-30002C2C-FC6C-41FD-8864-DA0B3F66ED58Q27852764-5672338A-065F-42F0-BE8A-5D8866048EA3Q28067486-47D64F4F-A224-4720-95D6-8ADBE113C726Q28071345-849E5E9E-0DEC-45EA-B060-DACA7138D6D2Q28072204-96DC7D69-7F5F-4CE4-872A-48087598992BQ28073673-A548F91C-33C1-4636-A5B2-2F248F0AB1D3Q28075761-7BACA850-008D-4C0F-868E-926E8DBB1B88Q28078658-F7BB8A4D-9A17-44C3-B9A4-3A179A55D702Q28082524-2DB6A660-589E-4C64-A71A-8FA7874521D7Q28247712-0E523D69-42D8-41E9-918E-4C5CE2CE225FQ28475552-C5553EF7-435A-447E-81A2-768549A3E9F6Q28484538-CBEC87C3-6E6D-4E42-A493-C6351F1BC5BCQ28607703-B528F24F-2892-45BB-B86D-D7205E132CFDQ29030215-45BBA43E-FA0F-4F22-9D48-166AA3392C2EQ30277998-6CE070C9-D1FB-4566-8295-BC53BD5708A2Q30497664-90CD00CB-2A1F-4E1C-93BB-6ADD871918E0Q33408735-90651ED7-C545-4987-8448-94ADAF4F27C8Q33439527-4B5900E1-6678-4AE7-8E9E-5E2994BB0229Q33521938-0EEB061F-F420-4349-9314-1724A38F27A8Q33557369-EAEB6A18-4D01-437A-A702-0C5C967AE533Q33560967-50F2D39E-461C-475F-A452-DDB37751B7E4Q33564013-95715AB1-0174-4B44-AA63-B9C4BCD27DEBQ33598001-DBF1E9DF-0F59-417C-AE66-DF440CE32545Q33598840-D3F48EC0-59BF-4898-B8F5-72F6CA788AB5Q33606699-19D63D68-1376-4CD7-BF2C-9F763ED3536DQ33618910-BB6B242A-02B2-4DF6-A674-73A4811242D5Q33622179-0E19D6FB-0874-4AFC-9384-9A3F7B8727F2Q33651791-1A924A62-7E8D-454C-B343-4A09CF9E5764Q33669053-F51B0848-3D0F-41AE-838E-26B397AD1291Q33685138-CE84A4D2-98CC-4121-9245-CBCF1F7A1C44Q33775647-A467FB9C-E1F8-4F04-9240-1BB1533BE6C0
P2860
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A synthetic lethal therapeutic approach: poly
@nl
A synthetic lethal therapeutic ...... NA double-strand break repair.
@en
type
label
A synthetic lethal therapeutic approach: poly
@nl
A synthetic lethal therapeutic ...... NA double-strand break repair.
@en
prefLabel
A synthetic lethal therapeutic approach: poly
@nl
A synthetic lethal therapeutic ...... NA double-strand break repair.
@en
P356
P1476
A synthetic lethal therapeutic ...... NA double-strand break repair.
@en
P2093
Alan Ashworth
P304
P356
10.1200/JCO.2008.16.0812
P407
P577
2008-06-30T00:00:00Z